구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | SGN-30 (anti-CD30 mAb) |
Overview Company | Seagen Inc. |
Overview Modality | ANTIBODY |
Overview Target | CD30 |
Overview Indication | Anaplastic Large-Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , pharmacokinetics, efficacy in different patient groups, safety, and tolerability |
PK/PD Half-life | 81 days |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closur |
Clinical Safety signal | pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closur |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02588651 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | SGN-30 (anti-CD30 mAb) |
Overview Company | Seagen Inc. |
Overview Modality | ANTIBODY |
Overview Target | CD30 |
Overview Indication | Anaplastic Large-Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , pharmacokinetics, efficacy in different patient groups, safety, and tolerability |
PK/PD Half-life | 81 days |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closur |
Clinical Safety signal | pneumonitis occurred in five patients receiving SGN-30 and GVD, leading to premature closur |
Clinical Selected reported efficacy | ORR 89.5% |
Clinical Reported ORR | 89.5% |
Clinical Result source | ClinicalTrials.gov NCT02588651 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02588651 |
추천 비교
추천 비교